b2b communications |
|||
News for 18-Sep-25 Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General |
The Best b2b communications websiteAll the b2b communications information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best b2b communications site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
b2b communications
Are you aware that many online stores offer weekly specials? Visit the b2b communications site and see what's on offer. There may be a special b2b communications sale but you won't know about it unless you take the time to investigate the site. Don't rush your shopping. When you're in a hurry to purchase b2b communications you may be tempted to quickly visit the store, place your b2b communications order and then log off. Check what else it available. You could be in for a special surprise. We feel so confident that your b2b communications shopping experience will be a good one that we have built this site so that you can go straight to the prime b2b communications retailer without wasting a lot of time checking out 100's of ordinary providers. Medical Newscast Resources b2b communications to visual basic online training
b2b communications -Saving Pediatric Drug Becomes Readily Available to Those in Need by: ARA Content
(ARA) - We can all sympathize with the frustration people experience waiting for a new drug that is being tested for a certain disorder. Imagine you have a child with a rare disorder and the only drug effective for treating the disorder is not only extremely hard to obtain, but available only through a nationally-administered random selection process. For many American families, this dilemma is a harsh reality. Patients suffering from a host of difficult to treat orphan disorders have found marked relief from using HP Acthar Gel. Some disorders Acthar helps include seizure complex in babies and young children, referred to as West's syndrome or infantile spasm; Still's disease and ulcerative colitis; Bell's palsy; multiple sclerosis; adrenocortical insufficiency and non-endocrine disorders that are responsive to glucocorticoids. For the past four years, however, the drug has only been available through a limited access program administered by the National Organization for Rare Disorders (NORD), a federation of more that 135 non-profit health organizations serving people with rare disorders. U.S. physicians who were interested in obtaining Acthar Gel for their patients with life-threatening or severely debilitating conditions who did not respond to any other treatment were given first access to the drug. Others with "non-life-threatening" cases had to enroll in a computerized random selection process administered by NORD. An estimated 1,600 patients, primarily suffering from West's syndrome and multiple sclerosis who experience episodes of "flare," have been allowed access to HP Acthar Gel each year for the past four years under the limited access program. More than 5,000 additional patients whose physicians requested the drug were denied. The origins of this drug shortage crisis date back to 1996 when Aventis Pharmaceuticals stopped making Acthar for a few months because of manufacturing difficulties. But now, Questcor Pharmaceuticals, Inc. (AMEX: QSC) has signed an agreement with Aventis to acquire the worldwide rights to HP Acthar Gel. Questcor has also reached a manufacturing agreement with Aventis and will gradually move production to an independent manufacturing facility. As a result, HP Acthar Gel is now back in full production and is returning to normal levels of distribution. Questcor began shipments of HP Acthar Gel to wholesalers the last week of September 2001, giving patients in need access to the product. "We are delighted that Questcor is making this critically important product more widely available after this long period of restricted distribution," said Abbey S. Meyers, president of NORD. "We have been working closely with the company over the last several months to ensure that anyone with a need for Acthar Gel is now able to readily receive the product through more traditional channels. Too many people have suffered as a result of limited access to Acthar Gel." Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company that serves the needs of acute and critical care hospitals with its proprietary products. Visit www.questcor.com for more information on the company and its products. If you are a patient with a disorder that can be treated with Acthar, ask your doctor to contact Questcor Pharmaceuticals at (510) 400-0700. For more information about Acthar, including distribution information, please visit www.Acthar.com.
|
||
http://www.medmeet.com/ |
MD Meetings Medical On the Net Real Time Media On The Net |